Mark S. Forman - 15 May 2025 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Chief Medical Officer
Signature
/s/ Austin Rutherford, as Attorney-in-Fact
Issuer symbol
VTYX
Transactions as of
15 May 2025
Net transactions value
+$3,090
Form type
4
Filing time
16 May 2025, 18:40:27 UTC
Previous filing
03 Jan 2025
Next filing
19 Nov 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Mark S. Forman filed Form 4 for Ventyx Biosciences, Inc. (VTYX) on 16 May 2025."

Quick Takeaways

  • This page summarizes Mark S. Forman's Form 4 filing for Ventyx Biosciences, Inc. (VTYX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 16 May 2025, 18:40.

What Changed

  • Previous filing in this sequence was filed on 03 Jan 2025.
  • Current net transaction value: +$3,090.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Forman Mark S Chief Medical Officer 12790 EL CAMINO REAL, SUITE 200, SAN DIEGO /s/ Austin Rutherford, as Attorney-in-Fact 16 May 2025 0001922353

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Award $3,090 +3,000 $1.03 3,000 15 May 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Ventyx Biosciences, Inc. 2021 Employee Stock Purchase Plan ("2021 ESPP"), for the ESPP Purchase Period (as defined in the 2021 ESPP) of November 15, 2024 through May 15, 2025. This transaction is also exempt under Rule 16b-3(c).
F2 The relevant Offering Period (as defined in the 2021 ESPP) ended, and the shares were acquired, on the Exercise Date (as defined in the 2021 ESPP) of May 15, 2025.
F3 In accordance with the 2021 ESPP, these shares were purchased based on 85% of the closing price on May 15, 2025.

Sponsored